Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Franck E. Nicolini, Michael J. Mauro, Giovanni Martinelli, Dong Wook Kim, Simona Soverini, Martin C. Müller, Andreas Hochhaus, Jorge Cortes, Charles Chuah, Inge H. Dufva, Jane F. Apperley, Fumiharu Yagasaki, Jay D. Pearson, Senaka Peter, Cesar Sanz Rodriguez, Claude Preudhomme, Francis Giles, John M. Goldman, Wei Zhou

Research output: Contribution to journalArticle

Abstract

The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-α in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.

Original languageEnglish (US)
Pages (from-to)5271-5278
Number of pages8
JournalBlood
Volume114
Issue number26
DOIs
StatePublished - Dec 17 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Epidemiologic Studies
Mutation
Survival
Hydroxyurea
Cytarabine
Chromosomes
Stem cells
Interferons
Hazards
Disease-Free Survival
Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Stem Cell Transplantation
Proportional Hazards Models
Medical Records
Observational Studies
Retrospective Studies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nicolini, F. E., Mauro, M. J., Martinelli, G., Kim, D. W., Soverini, S., Müller, M. C., ... Zhou, W. (2009). Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 114(26), 5271-5278. https://doi.org/10.1182/blood-2009-04-219410

Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. / Nicolini, Franck E.; Mauro, Michael J.; Martinelli, Giovanni; Kim, Dong Wook; Soverini, Simona; Müller, Martin C.; Hochhaus, Andreas; Cortes, Jorge; Chuah, Charles; Dufva, Inge H.; Apperley, Jane F.; Yagasaki, Fumiharu; Pearson, Jay D.; Peter, Senaka; Rodriguez, Cesar Sanz; Preudhomme, Claude; Giles, Francis; Goldman, John M.; Zhou, Wei.

In: Blood, Vol. 114, No. 26, 17.12.2009, p. 5271-5278.

Research output: Contribution to journalArticle

Nicolini, FE, Mauro, MJ, Martinelli, G, Kim, DW, Soverini, S, Müller, MC, Hochhaus, A, Cortes, J, Chuah, C, Dufva, IH, Apperley, JF, Yagasaki, F, Pearson, JD, Peter, S, Rodriguez, CS, Preudhomme, C, Giles, F, Goldman, JM & Zhou, W 2009, 'Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation', Blood, vol. 114, no. 26, pp. 5271-5278. https://doi.org/10.1182/blood-2009-04-219410
Nicolini, Franck E. ; Mauro, Michael J. ; Martinelli, Giovanni ; Kim, Dong Wook ; Soverini, Simona ; Müller, Martin C. ; Hochhaus, Andreas ; Cortes, Jorge ; Chuah, Charles ; Dufva, Inge H. ; Apperley, Jane F. ; Yagasaki, Fumiharu ; Pearson, Jay D. ; Peter, Senaka ; Rodriguez, Cesar Sanz ; Preudhomme, Claude ; Giles, Francis ; Goldman, John M. ; Zhou, Wei. / Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. In: Blood. 2009 ; Vol. 114, No. 26. pp. 5271-5278.
@article{4d995830bd4842d2b5930bc46a2e3233,
title = "Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation",
abstract = "The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57{\%} cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56{\%} of cases, hydroxyurea in 39{\%}, imatinib in 35{\%}, cytarabine in 26{\%}, MK-0457 in 11{\%}, stem cell transplantation in 17{\%}, and interferon-α in 6{\%} of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.",
author = "Nicolini, {Franck E.} and Mauro, {Michael J.} and Giovanni Martinelli and Kim, {Dong Wook} and Simona Soverini and M{\"u}ller, {Martin C.} and Andreas Hochhaus and Jorge Cortes and Charles Chuah and Dufva, {Inge H.} and Apperley, {Jane F.} and Fumiharu Yagasaki and Pearson, {Jay D.} and Senaka Peter and Rodriguez, {Cesar Sanz} and Claude Preudhomme and Francis Giles and Goldman, {John M.} and Wei Zhou",
year = "2009",
month = "12",
day = "17",
doi = "10.1182/blood-2009-04-219410",
language = "English (US)",
volume = "114",
pages = "5271--5278",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

AU - Nicolini, Franck E.

AU - Mauro, Michael J.

AU - Martinelli, Giovanni

AU - Kim, Dong Wook

AU - Soverini, Simona

AU - Müller, Martin C.

AU - Hochhaus, Andreas

AU - Cortes, Jorge

AU - Chuah, Charles

AU - Dufva, Inge H.

AU - Apperley, Jane F.

AU - Yagasaki, Fumiharu

AU - Pearson, Jay D.

AU - Peter, Senaka

AU - Rodriguez, Cesar Sanz

AU - Preudhomme, Claude

AU - Giles, Francis

AU - Goldman, John M.

AU - Zhou, Wei

PY - 2009/12/17

Y1 - 2009/12/17

N2 - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-α in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.

AB - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)+ acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph+ ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-α in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP,AP, BP, and Ph+ ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.

UR - http://www.scopus.com/inward/record.url?scp=73949111062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949111062&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-04-219410

DO - 10.1182/blood-2009-04-219410

M3 - Article

C2 - 19843886

AN - SCOPUS:73949111062

VL - 114

SP - 5271

EP - 5278

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -